Bromantane

Bromantane combines an adamantane cage with a para-bromophenylamine group. The adamantane half is the same rigid, fat-soluble diamond-fragment scaffold found in amantadine and memantine, and it is what lets the molecule cross into the brain and stay there; the bromophenyl half is what makes it different from either. It was developed in the Soviet programme for actoprotectors: drugs intended to preserve physical and mental work under stress without the oxygen demand or overt hyperstimulation of classic stimulants [5]. In Russia it later became Ladasten, a medicine for asthenic and neurasthenic disorders.

Two things make it unusual as a stimulant. Acute toxicity is very low — the reported mouse LD50 is 8100 mg/kg intraperitoneally — while the behavioural profile is genuinely stimulant-like: it activates both simple and complex forms of behaviour, produces the EEG changes typical of psychostimulants, antagonises drugs with a depressant neuropsychotropic action, and improves memory and complex operant performance in rats [6]. And unlike a classic stimulant, it is also anxiolytic, which is what the actoprotector concept was reaching for.

The human evidence is positive but concentrated in one research tradition. The key randomised study enrolled 30 adults with neurasthenia, 15 per arm. It was single-blind, used 100 mg a day for 28 days and reported that bromantane reduced core asthenic symptoms faster and further than placebo, without a withdrawal syndrome [1]. A separate multicentre programme analysed 728 patients given 50–100 mg a day for 28 days. It reported response rates of 76.0% on CGI-S and 90.8% on CGI-I, but had no randomised control group, so expectation, regression to the mean and the natural course of fatigue cannot be separated from drug effect [2].

A single 100 mg dose also improved psychophysiological measures during mental fatigue in healthy volunteers, with larger effects in stress-labile participants [7]. An earlier ten-person placebo comparison found EEG changes consistent with moderate vigilance but little change in untired operators' principal performance measures [8]. That is evidence for a state-dependent signal, not proof of broad cognitive enhancement.

No direct receptor target has been demonstrated. Bromantane is often described as dopaminergic, but the better evidence points to altered synthesis rather than the direct dopamine-transporter inhibition seen with Phenylpiracetam. In rats, a single 50 mg/kg oral dose changed tyrosine-hydroxylase messenger RNA and protein, L-DOPA and dopamine differently across the ventral tegmental area, nucleus accumbens, hypothalamus, striatum and hippocampus [4]. A separate expression study found increased genes for tyrosine hydroxylase and aromatic L-amino-acid decarboxylase, the rate-limiting and final enzymes in dopamine synthesis [3]. These are downstream genomic effects in animals; the initiating molecular sensor is unknown.

Direct monoamine-uptake effects appear only at high in-vitro concentrations. Bromantane inhibited synaptosomal dopamine and serotonin uptake at 50 µM, while norepinephrine uptake needed more than 500 µM [9]. No human study establishes that those concentrations occur in brain, so calling it a conventional reuptake inhibitor would overstate the evidence.

The dopamine signal can feed plasticity. In rat hippocampal slices, 10 µM bromantane converted short-term potentiation into a longer-lasting form. Anisomycin abolished the effect and the D1/D5 antagonist SCH23390 reduced it, pointing to new protein synthesis downstream of dopamine signalling rather than direct D1/D5 agonism [4]. Animal expression work also reports induction of neurotrophin and MAP-kinase pathways, but does not identify a binding target [10].

Older experiments found complex, region- and dose-dependent changes in dopamine and serotonin content [11]. Together they support an indirect monoaminergic drug, not the tidy story of a selective receptor ligand.

The anxiolytic half has its own mechanism, and it is corrective rather than sedative. A Russian study tested ladasten in two inbred rat strains chosen for opposite emotional-stress phenotypes. At 30 mg/kg intraperitoneally it produced an anxiolytic effect in the open field in MR rats and no effect at all in MNRA rats. In the same MR rats — and not in MNRA rats — a model stress disrupted the regulation of [3H]diazepam binding to the benzodiazepine site of the GABA-A receptor, and ladasten given at the anxiolytic dose prevented that stress-induced change [12].

Read carefully, that is not benzodiazepine-site agonism. What the experiment shows is that the drug stops stress from dysregulating the site, in the genotype where stress dysregulates it — and does nothing in the genotype where it does not. A drug whose anxiolytic effect is contingent on the animal's stress phenotype would explain why the human signal is strongest in fatigued, stress-labile participants and weakest in rested ones [7][8]. It is one study in one laboratory, and it has not been replicated outside that tradition.

So the honest summary of the mechanism is a drug with no identified binding site that appears to work by nudging two regulatory systems — dopamine synthesis and stress-driven GABA-A regulation — back toward baseline, with effects that show up mainly when baseline has been disturbed.

In the 30-person placebo trial, one participant reported mild internal restlessness; laboratory tests and ECG did not show a treatment signal, and no withdrawal syndrome appeared during the final placebo week [1]. In the 728-patient uncontrolled programme, adverse effects were reported by 3%, treatment was stopped in 0.8%, and no serious adverse event was reported [2]. These short Russian studies do not establish long-term or rare-event safety.

Bromantane is explicitly listed as a non-specified S6 stimulant prohibited in competition on the 2026 World Anti-Doping Agency list. Its appearance in elite sport and detection in doping control were documented in 1997 [13].